Peringatan Keamanan

Symptoms of overdose include drowsiness, weakness, nausea, dizziness, abdominal pain, cerebral oedema and renal tubular necrosis, hyperglycaemia and hypoglycaemia, liver damage, encephalopathy, coma and death.

Fludiazepam

DB01567

small molecule experimental illicit

Deskripsi

Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is a scheduled drug in the U.S., but is approved for use in Japan.

Struktur Molekul 2D

Berat 302.731
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

3 Data
  • 1. Avoid alcohol.
  • 2. Avoid grapefruit products.
  • 3. Limit caffeine intake.

Interaksi Obat

716 Data
Buprenorphine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Hydrocodone Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Magnesium sulfate The therapeutic efficacy of Fludiazepam can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Fludiazepam may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Mirtazapine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Orphenadrine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Pramipexole Fludiazepam may increase the sedative activities of Pramipexole.
Ropinirole Fludiazepam may increase the sedative activities of Ropinirole.
Rotigotine Fludiazepam may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Fludiazepam.
Suvorexant Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Thalidomide Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Clozapine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Clozapine.
Methadone Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Olanzapine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Olanzapine.
Phenytoin The serum concentration of Phenytoin can be increased when it is combined with Fludiazepam.
Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Fludiazepam.
Sodium oxybate Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Teduglutide The serum concentration of Fludiazepam can be increased when it is combined with Teduglutide.
Yohimbine The therapeutic efficacy of Fludiazepam can be increased when used in combination with Yohimbine.
Ethanol Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Fludiazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Zimelidine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Fludiazepam is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Fludiazepam is combined with Levomilnacipran.
Indalpine The risk or severity of adverse effects can be increased when Fludiazepam is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Fludiazepam is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Fludiazepam is combined with Alaproclate.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Fludiazepam.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Fludiazepam.
Zopiclone The risk or severity of adverse effects can be increased when Fludiazepam is combined with Zopiclone.
Caffeine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Caffeine.
Theophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theophylline.
Dyphylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Dyphylline.
Pentoxifylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Pentoxifylline.
Mercaptopurine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Mercaptopurine.
Aminophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline.
Oxtriphylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Oxtriphylline.
Theobromine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theobromine.
Fenethylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Fenethylline.
8-azaguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 8-azaguanine.
7,9-Dimethylguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 7,9-Dimethylguanine.
Xanthine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Xanthine.
7-Deazaguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 7-Deazaguanine.
Guanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Guanine.
9-Methylguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 9-Methylguanine.
Peldesine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Peldesine.
Hypoxanthine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Hypoxanthine.
9-Deazaguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 9-Deazaguanine.
Propentofylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Propentofylline.
Valomaciclovir The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Valomaciclovir.
3-isobutyl-1-methyl-7H-xanthine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
Uric acid The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Uric acid.
Doxofylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Doxofylline.
6-O-benzylguanine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 6-O-benzylguanine.
Lisofylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Lisofylline.
Lobucavir The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Lobucavir.
Cafedrine The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Cafedrine.
Theodrenaline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Theodrenaline.
Bamifylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Bamifylline.
Proxyphylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Proxyphylline.
Acefylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Acefylline.
Etamiphylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Etamiphylline.
Pentifylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Pentifylline.
Bufylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Bufylline.
Bromotheophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Bromotheophylline.
Furafylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Furafylline.
8-chlorotheophylline The therapeutic efficacy of Fludiazepam can be decreased when used in combination with 8-chlorotheophylline.
PCS-499 The therapeutic efficacy of Fludiazepam can be decreased when used in combination with PCS-499.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Fludiazepam.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Fludiazepam.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Fludiazepam.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Fludiazepam.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Fludiazepam.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Fludiazepam.

Target Protein

Gamma-aminobutyric acid receptor subunit alpha-1 GABRA1
Translocator protein TSPO
Gamma-aminobutyric acid receptor subunit alpha-2 GABRA2
Gamma-aminobutyric acid receptor subunit alpha-3 GABRA3
Gamma-aminobutyric acid receptor subunit alpha-5 GABRA5
Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1
Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2
Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3
Gamma-aminobutyric acid receptor subunit beta-1 GABRB1
Gamma-aminobutyric acid receptor subunit beta-2 GABRB2
Gamma-aminobutyric acid receptor subunit beta-3 GABRB3
Gamma-aminobutyric acid receptor subunit delta GABRD
Gamma-aminobutyric acid receptor subunit epsilon GABRE
Gamma-aminobutyric acid receptor subunit pi GABRP
Gamma-aminobutyric acid receptor subunit rho-1 GABRR1
Gamma-aminobutyric acid receptor subunit rho-2 GABRR2
Gamma-aminobutyric acid receptor subunit rho-3 GABRR3

Referensi & Sumber

Synthesis reference: Yamamato, H., Inaba, S.,Okamoto, T., Hirohashi, T., Ishizumi, K., Yamamoto, M., Maruyama, l., Mori, K. and Kobayashi, T.; U.S. Patents 3,723,461; March 27, 1973; 3,828,027; August 6, 1974 and 3,925,364; December 9, 1975; all assigned to Sumitomo Chemical Co., Ltd.
Artikel (PubMed)
  • PMID: 2855634
    Ishiwata K, Yanai K, Ido T, Miura-Kanno Y, Kawashima K: Synthesis and biodistribution of 11Cfludiazepam for imaging benzodiazepine receptors. Int J Rad Appl Instrum B. 1988;15(4):365-71.
  • PMID: 2857046
    Nakatsuka I, Shimizu H, Asami Y, Katoh T, Hirose A, Yoshitake A: Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Erispan — Sumitomo

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul